Seer CFO Exits as Proteomics Company Names Internal Successor…

Event summary

David Horn, Seer’s CFO and President, departs October 1, 2026 for a private company role after six years.
Charles Endweiss, VP of Financial Planning & Analysis, promoted to Treasurer and principal financial officer.
Endweiss brings nearly five years of experience at Seer and prior roles in finance and operations at Carbon.
Seer’s Proteograph® Product Suite remains core focus amid leadership transition.

The big picture

Seer’s CFO transition comes as the proteomics company seeks to solidify its market position with its Proteograph® Product Suite. The shift in leadership highlights the importance of financial stewardship in scaling biotech operations, particularly as Seer navigates competitive pressures in the proteomics space. The move also underscores the trend of internal promotions in biotech finance roles, reflecting the sector’s emphasis on institutional knowledge.

What we're watching

Leadership Stability: Whether Charles Endweiss can maintain financial continuity amid Horn’s departure.
Strategic Focus: How the transition impacts Seer’s push for deeper proteomic insights and market positioning.
Operational Momentum: The pace at which Endweiss integrates into the CFO role and aligns with Seer’s long-term goals.